

CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)

**INITIAL PUBLIC OFFERING OF ASSOCIATED COMPANY, BIOLIDICS LIMITED (FORMERLY
KNOWN AS CLEARBRIDGE BIOMEDICS PTE. LTD.)**

1. LISTING OF ASSOCIATED COMPANY, BIOLIDICS LIMITED

The board of directors (the "**Board**") of Clearbridge Health Limited (the "**Company**") refers to the Company's announcements ("**Announcements**") dated 28 June 2018, 19 July 2018, 26 November 2018 and 11 December 2018 in relation to the Listing.

Further to the Announcements, the Board is pleased to announce that Biolidics was listed on the Catalist Board of the SGX-ST today.

Following the completion of the IPO and as at the date of this announcement, the Company's shareholding interest (direct and indirect) in Biolidics decreased to approximately 35.47%.

2. FINANCIAL EFFECT OF THE IPO

The financial effects of the IPO on the Group are set out below and are purely for illustrative purposes. The pro forma financial effects of the IPO on the Group's net tangible asset ("**NTA**") and loss per share ("**LPS**") have been computed based on (a) the Group's audited consolidated financial statements for the financial year ended 31 December 2017 ("**FY2017**"); (b) the Group's unaudited consolidated financial statements for the financial period ended 30 September 2018; and (c) the unaudited fair value movements of the investment in associated company, Biolidics, based on an enlarged issue share capital of 242,500,000 shares and an Issue Price of S\$0.28 per share.

2.1 NTA

The pro forma financial effect of the IPO on the NTA per share of the Group as at 31 December 2017, assuming the IPO had completed on 31 December 2017, is as follows:

	Before the IPO	After the IPO
NTA attributable to owners of the Company (S\$'000)	60,940	58,420
Number of shares in issue	481,000,000	481,000,000
NTA per share (Singapore cents)	12.67	12.15

The pro forma financial effect of the IPO on the NTA per share of the Group as at 30 September 2018, assuming the IPO had completed on 30 September 2018, is as follows:

	Before the IPO	After the IPO
NTA attributable to owners of the Company (S\$'000)	48,952	55,572
Number of shares in issue	489,310,702	489,310,702
NTA per share (Singapore cents)	10.00	11.36

2.2 LPS

The pro forma financial effect of the IPO on the LPS for FY2017, assuming the IPO had completed on 1 January 2017, is as follows:

	Before the IPO	After the IPO
Loss attributable to owners of the Company (S\$'000)	7,470	9,988
Number of shares in issue	481,000,000	481,000,000
LPS (Singapore cents)	1.55	2.08

The pro forma financial effect of the IPO on the LPS for the financial period ended 30 September 2018, assuming the IPO had completed on 1 January 2018, is as follows:

	Before the IPO	After the IPO
Loss attributable to owners of the Company (S\$'000)	16,223	9,603
Number of shares in issue	489,310,702	489,310,702
LPS (Singapore cents)	3.32	1.96

3. **TRADING CAUTION**

Shareholders and other investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisors if there are in doubt about the actions they should take.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

19 December 2018

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*